CLAIMS

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

B^{1A} is selected from the group consisting of:


,

,

,

,

,

and

;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is selected from the group consisting of hydrogen, $-C(=O)R^{K2}$ and $-C(=O)OR^{L2}$;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{M2}$ and $-C(=O)OR^{N2}$;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is selected from the group consisting of hydrogen, $-C(=O)R^{P2}$ and $-C(=O)OR^{Q2}$;

R^{D2} is selected from the group consisting of hydrogen, deuterium, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{R2}$ and $-C(=O)OR^{S2}$;

R^{F2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

Y^2 and Y^3 are independently N or CR^{I2}, wherein R^{I2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;

R^{G2} is an optionally substituted C_{1-6} alkyl;

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{U2}$ and $-C(=O)OR^{V2}$; and

R^{K2}, R^{L2}, R^{M2}, R^{N2}, R^{P2}, R^{Q2} R^{R2}, $R^{S2,}$ R^{U2} and R^{V2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heterocyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heterocyclyl(C_{1-6} alkyl);

R^A is hydrogen;

R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid, ,  and ;

R^{a1} and R^{a2} are each hydrogen;

R^{2A} is a C_{1-6} azidoalkyl;

R^{3A} is selected from the group consisting of OH, $-OC(=O)R''^{A}$ and an optionally substituted O-linked amino acid;

R^{4A} is halogen;

R^{5A} is hydrogen or halogen;

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{3-24} alkenyl, an optionally substituted C_{3-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted $*-(CR^{15A}R^{16A})_p-O-C_{1-24}$ alkyl, an optionally substituted $*-(CR^{17A}R^{18A})_q-O-C_{1-24}$ alkenyl,


,

,

,

and

; or

R^{6A} is

and R^{7A} is absent or hydrogen; or

R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted

and an optionally substituted

, wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system;

R^{9A} is selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, $NR^{30A}R^{31A}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

each R^{15A}, each R^{16A}, each R^{17A} and each R^{18A} are independently hydrogen, an optionally substituted C_{1-24} alkyl or alkoxy;

R^{19A}, R^{20A}, R^{22A} and R^{23A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{21A} and R^{24A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl and an optionally substituted –O–aryl;

R^{25A} and R^{29A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{26A} and R^{27A} are independently -C≡N or an optionally substituted substituent selected from the group consisting of C_{2-8} organylcarbonyl, C_{2-8} alkoxycarbonyl and C_{2-8} organylaminocarbonyl;

R^{28A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

R^{30A} and R^{31A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

$R^{"A}$ is an optionally substituted C_{1-24}-alkyl;

m is 0 or 1;

t is 0;

p and q are independently selected from the group consisting of 1, 2 and 3;

r is 1 or 2;

s is 0; and

Z^{1A}, Z^{2A}, Z^{3A} and Z^{4A} are independently O or S.

2. The compound of Claim 1, wherein R^{2A} is azidomethyl.

3. The compound of any one of Claims 1-2, wherein R^{1A} is .

4. The compound of Claim 3, wherein R^{6A} and R^{7A} are both hydrogen.

5. The compound of Claim 3, wherein R^{6A} and R^{7A} are both absent.

6. The compound of Claim 3, wherein both R^{6A} and R^{7A} are independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{3-24} alkenyl, an optionally substituted C_{3-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl).

7. The compound of Claim 3, wherein R^{6A} and R^{7A} are both an optionally substituted C_{1-24} alkyl.

8. The compound of Claim 3, wherein R^{6A} and R^{7A} are both an optionally substituted C_{3-24} alkenyl.

9. The compound of Claim 3, wherein R^{6A} and R^{7A} are both *–$(CR^{15A}R^{16A})_p$–O–C_{1-24} alkyl.

10. The compound of Claim 3, wherein R^{6A} and R^{7A} are both *–$(CR^{17A}R^{18A})_q$–O–C_{2-24} alkenyl.

11. The compound of Claim 3, wherein R^{6A} and R^{7A} are both an optionally substituted aryl.

12. The compound of Claim 3, wherein R^{6A} and R^{7A} are both an optionally substituted aryl(C_{1-6} alkyl).

13. The compound of Claim 3, wherein R^{6A} and R^{7A} are both .

14. The compound of Claim 3, wherein R^{6A} and R^{7A} are both .

15. The compound of Claim 3, wherein R^{6A} and R^{7A} are both .

16. The compound of Claim 3, wherein R^{6A} and R^{7A} are both .

17. The compound of Claim 3, wherein R^{6A} and R^{7A} are both .

18. The compound of Claim 3, wherein R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system.

19. The compound of any one of Claims 1-18, wherein Z^{1A} is O.

20. The compound of any one of Claims 1-18, wherein Z^{1A} is S.

21. The compound of Claim 1, wherein R^{1A} is .

22. The compound of Claim 21, wherein R^{8A} is hydrogen, and R^{9A} is $NR^{30A}R^{31A}$, wherein R^{30A} and R^{31A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl.

23. The compound of Claim 21, wherein R^{8A} is an optionally substituted aryl; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

24. The compound of Claim 21, wherein R^{8A} is an optionally substituted aryl; and R^{9A} has the structure , wherein R^{33A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{34A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{35A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{34A} and R^{35A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

25. The compound of any one of Claims 21-24, wherein Z^{2A} is O.

26. The compound of any one of Claims 21-24, wherein Z^{2A} is S.

27. The compound of Claim 1, wherein R^{1A} is .

28. The compound of Claim 27, wherein R^{10A} and R^{11A} are both an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

29. The compound of Claim 27, wherein R^{10A} and R^{11A} independently have the structure , wherein R^{36A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{37A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{38A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{37A} and R^{38A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

30. The compound of any one of Claims 27-29, wherein Z^{3A} is O.

31. The compound of any one of Claims 27-29, wherein Z^{3A} is S.

32. The compound of Claim 1, wherein R^{1A} is ; and R^{6A} is .

33. The compound of Claim 32, wherein m is 0; and R^{12A} and R^{13A} are independently absent or hydrogen.

34. The compound of Claim 32, wherein m is 1; and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

35. The compound of Claim 1, wherein R^{1A} is H.

36. The compound of Claim 1, wherein R^{1A} is an optionally substituted acyl.

37. The compound of Claim 1, wherein R^{1A} is an optionally substituted O-linked amino acid.

38. The compound of Claim 1, wherein R^{1A} is , wherein R^{40A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{41A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{40A} and R^{41A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

39. The compound of any one of Claims 1-38, wherein B^{1A} is .

40. The compound of any one of Claims 1-38, wherein B^{1A} is .

41. The compound of any one of Claims 1-38, wherein B^{1A} is .

42. The compound of any one of Claims 1-38, wherein B^{1A} is .

43. The compound of any one of Claims 1-38, wherein B^{1A} is .

44. The compound of any one of Claims 1-38, wherein B^{1A} is .

45. The compound of any one of Claims 1-44, wherein R^{3A} is OH.

46. The compound of any one of Claims 1-44, wherein R^{3A} is $-OC(=O)R^{"A}$.

47. The compound of any one of Claims 1-44, wherein R^{3A} is O-linked amino acid.

48. The compound of any one of Claims 1-44, wherein R^{3A} is , wherein R^{42A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{43A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{42A} and R^{43A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

49. The compound of any one of Claims 1-48, wherein R^{5A} is hydrogen.

50. The compound of any one of Claims 1-48, wherein R^{5A} is halogen.

51. The compound of Claim 50, wherein R^{5A} is fluoro or chloro.

52. The compound of any one of Claims 1-51, wherein R^{4A} is fluoro.

53. The compound of any one of Claims 1-51, wherein R^{4A} is chloro.

54. The compound of any one of Claims 1-53, wherein a compound of Formula (I), or a pharmaceutically acceptable salt, cannot be  .

55. The compound of Claim 1, wherein the compound of Formula (I) is:  , or a pharmaceutically acceptable salt thereof.

56. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of:

 ,
 ,
 ,
 ,
 ,
 ,



and


, or a pharmaceutically acceptable salt of any of the foregoing.

57. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

58. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

59. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

60. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

61. The compound of Claim 1, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

62. The compound of Claim 1, wherein the compound of Formula (I) is selected from the group consisting of:



,



,



,



,


,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

63. The compound of Claim 1, wherein the compound is selected from the group consisting of:


,

,

,

,

,



,



,



,



,



,



,



,



,



and



, or a pharmaceutically acceptable salt of any of the foregoing.

64. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-63, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

65. Use of an effective amount of a compound of any one of Claims 1-63, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating a paramyxovirus viral infection, wherein the paramyxovirus viral infection is selected from the group consisting of a human respiratory syncytial viral infection, a human parainfluenza viral infection and a human metapneumoviral infection.

66. Use of an effective amount of a compound of any one of Claims 1-63, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting replication of a paramyxovirus, wherein the paramyxovirus is selected from the group consisting of a human respiratory syncytial virus, a human parainfluenza virus and a human metapneumovirus.

67. Use of an effective amount of a compound of any one of Claims 1-63 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for contacting a cell infected with a paramyxovirus, wherein the paramyxovirus is selected from the group consisting of a human respiratory syncytial virus, a human parainfluenza virus and a human metapneumovirus.

68. The use of any one of Claims 65-67, wherein the paramyxovirus is a human respiratory syncytial virus.

69. The use of any one of Claims 65-67, wherein the paramyxovirus is a human parainfluenza virus.

70. The use of Claim 69, wherein human parainfluenza virus is a human parainfluenza virus 3.

71. The use of any one of Claims 65-67, wherein the paramyxovirus is a human metapneumovirus.